Talzenna (talazoparib) / Pfizer 
Welcome,         Profile    Billing    Logout  
 78 Diseases   59 Trials   59 Trials   2462 News 
86 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Talzenna (talazoparib) / Pfizer
TALAPRO-2, NCT03395197 / 2017-003295-31: Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

Hourglass May 2023 - Dec 2023 : Market entry in combination with Xtandi for metastatic CRPC (based on TALAPRO-2 trial)
Hourglass Oct 2022 - Dec 2022 : Approval for 1L mCRPC in combination with Xtandi
Checkmark Data from TALAPRO-2 trial in combination with Xtandi for metastatic CRPC
Oct 2022 - Oct 2022: Data from TALAPRO-2 trial in combination with Xtandi for metastatic CRPC
Checkmark Data from TALAPRO-2 trial in combination with Xtandi for mCRPC
More
Active, not recruiting
3
1054
Europe, Canada, Japan, US, RoW
Talazoparib with enzalutamide, Placebo with enzalutamide
Pfizer, Astellas Pharma Inc
mCRPC
10/22
12/25
TALAPRO-3, NCT04821622 / 2021-000248-23: Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Calendar Jan 2025 - Jun 2025: From TALAPRO-3 trial for 1L metastatic CRPC
Hourglass May 2023 - Dec 2023 : Market entry in combination with Xtandi for metastatic CRPC (based on TALAPRO-2 trial)
Active, not recruiting
3
599
Europe, Canada, Japan, US, RoW
talazoparib plus enzalutamide, Combination arm, Placebo plus enzalutamide, Monotherapy arm
Pfizer, Astellas Pharma Inc
Prostate Cancer
09/25
08/27
NCT05059522 / 2021-002457-29: Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Active, not recruiting
3
67
Europe, Canada, Japan, US, RoW
Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib, CMP 001, Utomilumab, PF04518600
Pfizer
Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors
09/26
09/26
2018-002914-10: FUnctional selection of advanced breast cancer patients for Talazoparib treatment Using the REpair Capacity (RECAP) test: The FUTURE trial Selectie van patiënten met uitgezaaide borstkanker voor behandeling met Talazoparib met behulp van de REpair Capacity (RECAP) test: De FUTURE studie

Not yet recruiting
2
66
Europe
Talazoparib, Capsule
Erasmus MC Cancer Institute, Pfizer
Advanced or metastatic breast cancer Vergevorderd of gemetastaseerd mammacarcinoom, Advanced or metastatic breast cancer Vergevorderde of uitgezaaide borstkanker, Diseases [C] - Cancer [C04]
 
 
FUTURE, NCT06193525: FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test

Recruiting
2
66
Europe
Talazoparib, Talazoparib 1 MG Oral Capsule [Talzenna]
Erasmus Medical Center, Leiden University Medical Center, University Medical Center Groningen
Advanced Breast Cancer
12/25
12/25
NCT02401347: Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Checkmark Genomic analysis from the Beyond BRCA clinical trial
Dec 2020 - Dec 2020: Genomic analysis from the Beyond BRCA clinical trial
Checkmark Initiation of P2 Beyond BRCA registrational trial in breast cancer
Aug 2015 - May 2015: Initiation of P2 Beyond BRCA registrational trial in breast cancer
Completed
2
21
US
Talazoparib Tosylate, BMN 673
Melinda Telli, BioMarin Pharmaceutical, Pfizer
Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer
12/19
12/22
2019-004388-37: A Three-Cohort Phase II trial to Assess the Efficacy of a Maintenance Treatment with TALAzoparib following First Line Platinum-based Chemotherapy in Pleural and Malignant Peritoneal MESOthelioma Patients: TALAMESO

Not yet recruiting
2
40
Europe
Capsule, TALZENNA
Hospices Civils de Lyon, PFIZER
This study involves adults subjects with advanced malignant pleural (cohort A) or peritoneal (cohorts B1 and B2) mesothelioma.The cohorts B1 will be patient populations with non-resected or incompletely resected disease and cohort B2, with completely resected disease., This study involves adults subjects with advanced malignant pleural (cohort A) or peritoneal (cohorts B1 and B2) mesothelioma., Not possible to specify
 
 
Talapro-1, NCT03148795 / 2016-002036-32: A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

Checkmark Additional data for metastatic castration-resistant 2L prostate cancer from TALAPRO-1 study
Aug 2021 - Aug 2021: Additional data for metastatic castration-resistant 2L prostate cancer from TALAPRO-1 study
Checkmark From TALAPRO-1 study for heavily pretreated mCRPC
Apr 2021 - Apr 2021: From TALAPRO-1 study for heavily pretreated mCRPC
Checkmark From TALAPRO-1 trial for mCRPC at ASCO 2020
More
Completed
2
128
Europe, US, RoW
Talazoparib, MDV3800
Pfizer, Medivation, Inc.
Prostate Cancer
09/20
03/23
2020-001105-24: TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma: A single-arm Phase 2 trial TALazoparib et Avelumab en tant que traitement d'entretien dans le carcinome urothélial métastatique ou localement avancé: un essai de phase 2 à un seul bras

Not yet recruiting
2
50
Europe
Avelumab, Talazoparib, MSB0010718C, PF-06944076, Concentrate for solution for infusion, Capsule, BAVENCIO, TALZENNA
Centre François Baclesse, Centre François Baclesse
Maintenance treatment in patients with locally advanced/metastatic urothelial carcinoma. Traitement de maintenance des patients présentant un carcinome urothelial métastatique ou localement avancé, Maintenance treatment in patients with locally advanced/metastatic urothelial carcinoma. Traitement de maintenance des patients présentant un carcinome urothelial métastatique ou localement avancé, Diseases [C] - Cancer [C04]
 
 
2020-003395-41: Ex vivo drug sensitivity in metastatic colorectal cancer

Not yet recruiting
2
45
Europe
Alectinib, Crizotinib, Dasatinib, Everolimus, Gemcitabine, Idelalisib, Larotrectinib, Methotrexate, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Trastuzumab, Talazoparib, Venetoclax, Cetuximab, Encorafinib, Capsule, hard, Film-coated tablet, Tablet, Infusion, Injection, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Alecensa, Xalkori, Sprycel, Afinitor, Gemcitabine Accord, Zydelig, Vitrakvi, Methotrexat Accord, Ibrance, Farydak, Keytruda, Perjeta, Herceptin, Talzenna, Venclyxto, Erbitux, Braftovi
Oslo University Hospital, Oslo University Hospital
Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Diseases [C] - Cancer [C04]
 
 
TALAMESO, NCT04462809 / 2019-004388-37: Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma

Not yet recruiting
2
40
NA
Talazoparib
Hospices Civils de Lyon, PFIZER
Advanced Malignant Pleural or Peritoneal Mesothelioma
03/21
10/24
Young-PALETTA, NCT04819243: PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study

Recruiting
2
178
RoW
Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib, Atezolizumab, Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib,
Samsung Medical Center
Premenopausal HR+/HER2- Metastatic Breast Cancer
12/25
12/27
LUNG-MAP Sub-Study, NCT04173507: Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

Completed
2
47
US
Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Talazoparib, BMN 673, BMN-673, Talazoparib Tosylate, Talzenna
SWOG Cancer Research Network, National Cancer Institute (NCI)
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
11/21
05/24
NCT04824937: Telaglenastat + Talazoparib In Prostate Cancer

Not yet recruiting
2
30
US
Telaglenastat, CB 839, Talazoparib, Taken orally
Massachusetts General Hospital, Calithera Biosciences, Inc, Pfizer, Prostate Cancer Foundation
Prostate Cancer Metastatic
12/21
12/21
NCT03565991 / 2018-000345-39: Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Checkmark Results from JAVELIN BRCA/ATM trial for advanced BRCA1/2-altered or ATM-altered solid tumors
Nov 2022 - Nov 2022: Results from JAVELIN BRCA/ATM trial for advanced BRCA1/2-altered or ATM-altered solid tumors
Checkmark For JAVELIN BRCA/ATM trial in combination with talazoparib for BRCA or ATM mutant solid tumors
Mar 2022 - Mar 2022: For JAVELIN BRCA/ATM trial in combination with talazoparib for BRCA or ATM mutant solid tumors
Terminated
2
202
Europe, Japan, US
Avelumab, Bavencio, Talazoparib, MDV3800, BMN 673
Pfizer
Locally Advanced or Metastatic Solid Tumors, Genes, BRCA 1
03/22
02/23
HCRN BRE19-433, NCT04690855: A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer

Terminated
2
1
US
Talazoparib, Talzenna, Atezolizumab, Tecentriq, Radiation
Mylin A. Torres, MD, Genentech, Inc., Pfizer, Emory University
Breast Cancer, Triple Negative Breast Cancer
02/22
12/22
TAC-GReD, NCT04740190: Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

Recruiting
2
33
RoW
Talazoparib, Carboplatin, whole brain irradiation
The University of Hong Kong
Recurrent Glioma, Recurrent Glioblastoma, Poly ADP Ribose Polymerase (PARP) Inhibitor, PTEN Gene Inactivation, IDH Mutation
12/22
12/23
NCT04892693: Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Recruiting
2
70
RoW
Talazoparib Oral Capsule, Single arm; Talazoparib
Seoul National University Hospital
Advanced Breast Cancer
05/27
05/27
TALASUR, NCT04678362 / 2020-001105-24: TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma

Recruiting
2
50
Europe
Talazoparib + Avelumab
Centre Francois Baclesse, Pfizer
Urothelial Carcinoma
07/23
12/25
TRIO-US L-07, NCT03672773: Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Recruiting
2
28
US
Talazoparib, BMN 673, BMN-673, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
Jonsson Comprehensive Cancer Center, Translational Research in Oncology, Pfizer
Recurrent Extensive Stage Small Cell Lung Carcinoma, Refractory Extensive Stage Small Cell Lung Carcinoma
10/25
10/26
NCT04187833: Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes

Completed
2
8
US
Nivolumab, Opdivo, Talazoparib, Talzenna
Case Comprehensive Cancer Center
Metastatic or Unresectable Melanoma
10/23
10/23
NCT04550494: Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Recruiting
2
36
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Talazoparib, BMN 673, BMN-673, BMN673
National Cancer Institute (NCI)
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, HER2-Positive Breast Carcinoma, Locally Advanced Breast Carcinoma, Locally Advanced Gastric Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Ovarian Carcinoma, Locally Advanced Pancreatic Carcinoma, Locally Advanced Prostate Carcinoma, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Prostate Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Breast Carcinoma, Recurrent Gastric Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
12/26
12/26
NCT04734730: Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Recruiting
2
70
US
Abiraterone Acetate, CB7630, Yonsa, Zytiga, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Degarelix, FE200486, Firmagon, Goserelin Acetate, ZDX, Zoladex, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Questionnaire Administration, Talazoparib, BMN 673, BMN-673
City of Hope Medical Center, National Cancer Institute (NCI)
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
08/27
08/27
NCT04692662: Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response

Recruiting
2
36
US
talazoparib
National Cancer Institute (NCI)
Solid Tumors
12/23
12/23
NCT03990896: Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Recruiting
2
30
US
Talazoparib, Talzenna
Massachusetts General Hospital, Pfizer
Breast Cancer
07/25
12/25
NCT03901469 / 2018-003906-26: A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer

Terminated
2
115
Europe, US, RoW
ZEN003694, ZEN-3694, Talazoparib, Talzenna
Zenith Epigenetics, Pfizer, Newsoara Biopharma Co., Ltd.
Triple Negative Breast Cancer
03/24
03/24
KCSG BR21-10, NCT04755868: Talazoparib Maintenance Therapy in Triple-negative Breast Cancer

Not yet recruiting
2
206
RoW
Talazoparib, Placebo
Yonsei University
TNBC - Triple-Negative Breast Cancer
03/24
03/24
NCT04756765: Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Recruiting
2
30
US
Talazoparib Tosylate, Talzenna, BMN-673
Stanford University, Pfizer
Breast Cancer, Advanced Breast Cancer
03/25
03/25
NCT05288127: Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature

Recruiting
2
55
RoW
Talazoparib
University of Malaya, Cancer Research Malaysia, Pfizer, Pantai Hospital Kuala Lumpur, Hospital Sultan Ismail
HRD 100 Gene Expression High, Triple Negative Breast Cancer
06/24
11/25
TEAM PC, NCT06582628: Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer:

Recruiting
2
78
Europe
Enzalutamide capsule, Enzalutamide capsule and Talazoparib capsule
Fundacion Oncosur
Metastatic Prostate Cancer
01/26
10/27
NCT04068831: Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

Completed
2
18
US
Talazoparib, BMN-673, Avelumab
Memorial Sloan Kettering Cancer Center
Metastatic Renal Cell Carcinoma, Fumarate Hydratase Deficient Renal Cell Carcinoma, Succinate Dehydrogenase Deficient Renal Cell Carcinoma
12/23
12/23
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
4200
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
12/27
12/28
ChiCTR2300078496: A single-center, non-interventional study to evaluate effectiveness and safety of Talazoparib in combination with Enzalutamide in first-line treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer(mCRPC) in China

Recruiting
2
10
 
none
Shanghai Jiaotong University School of Medicine Ruijin-Hainan Hospital(Hainan Boao Research Hopspital); Shanghai Jiaotong University School of Medicine Ruijin-Hainan Hospital(Hainan Boao Research Hopspital), Pfizer,only funding
Prostate cancer
 
 
NCT02912572: Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

Active, not recruiting
2
106
US
Avelumab, Talazoparib, Axitinib
Dana-Farber Cancer Institute, Pfizer
Metastatic Endometrial Cancer
11/23
11/26
TALENT, NCT06844383: A Study of Talazoparib with or Without Enzalutamide in People with Prostate Cancer Who Have Previously Received Abiraterone Acetate

Not yet recruiting
2
126
US
Talazoparib with enzalutamide, Talzenna, Xtandi, Talazoparib
Prostate Cancer Clinical Trials Consortium, Pfizer, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center
Prostate Cancer (Adenocarcinoma), MCRPC (metastatic Castration-resistant Prostate Cancer)
12/28
03/29
ZZFIRST, NCT04332744 / 2019-003096-20: Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)

Active, not recruiting
2
54
Europe
Enzalutamide, Xtandi, Talazoparib, (PF-06944076)
MedSIR, Pfizer
Metastatic Prostate Cancer
05/25
07/25
NCT06762808: Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

Not yet recruiting
2
55
US
Atezolizumab, Talazoparib
M.D. Anderson Cancer Center, Genentech, Inc., Strategic Alliance
Squamous Cell Carcinoma
12/26
12/28
NCT05327010: Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Recruiting
2
88
US
BET Bromodomain Inhibitor ZEN-3694, BETi ZEN-3694, ZEN 3694, ZEN-3694, ZEN003694, Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Diagnostic Imaging Testing, Diagnostic Imaging, Medical Imaging, Talazoparib, BMN 673, BMN-673, BMN673
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
08/25
08/25
NCT05071937: ZEN003694 Combined with Talazoparib in Patients with Recurrent Ovarian Cancer

Recruiting
2
33
US
ZEN003694, Talazoparib
Alexander B Olawaiye, MD, Pfizer, Zenith Epigenetics
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
12/29
03/31
SWOG S1929, NCT04334941: Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

Active, not recruiting
2
94
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Talazoparib, BMN 673, BMN-673, BMN673
National Cancer Institute (NCI)
Extensive Stage Lung Small Cell Carcinoma
11/25
11/25
NCT02286687: Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

Active, not recruiting
2
150
US
Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib, BMN 673, BMN-673
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Neoplasm, ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Metastatic Malignant Neoplasm, PALB2 Gene Mutation, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
12/25
12/25
NCT05142241: Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

Suspended
2
34
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Talazoparib, BMN 673, BMN-673, BMN673, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
National Cancer Institute (NCI)
Adrenal Gland Pheochromocytoma, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Paraganglioma
04/26
04/26
Strata PATH, NCT05097599: StrataPATH™ (Precision Indications for Approved Therapies)

Terminated
2
11
US
lorlatinib, encorafenib + binimetinib, talazoparib, sacituzumab govitecan, axitinib, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, enfortumab vedotin, Padcev
Strata Oncology, Merck Sharp & Dohme LLC, Pfizer, Gilead Sciences
Cancer, Advanced Solid Tumor
06/24
06/24
NCT05873192: Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

Not yet recruiting
2
30
US
ADT, Hormone Therapy, Enzalutamide, MDV3100, XTANDI®, Talazoparib, BMN 673, Talazoparib tosylate, Degarelix, Luprolide
M.D. Anderson Cancer Center
Prostate Cancer
12/26
12/28
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

Active, not recruiting
2
197
US
Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077
Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer Research
Breast Cancer, Triple Negative Breast Cancer
01/29
01/34
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
EVIDENT, NCT05725200 / 2020-003395-41: Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Recruiting
2
40
Europe
Alectinib, Cetuximab, Crizotinib, Dasatinib, Everolimus, Encorafenib, Gemcitabine, Idelalisib, Larotrectinib, Methotrexate, Palbociclib, Panobinostat, Pembrolizumab, Petrozumab, Trastuzumab, Talazoparib, Venetoclax
Oslo University Hospital, Oslo University Hospital
Metastatic Colorectal Cancer
12/38
12/40
NCT02878785: Decitabine and Talazoparib in Untreated AML and R/R AML

Completed
1/2
25
US
Decitabine, dacogen, talazoparib, BMN673; MDV3800
University of Maryland, Baltimore, Pfizer, Van Andel Research Institute
Acute Myeloid Leukemia
01/20
11/20
2018-000124-34: Safety and clinical Activity of avelumab in combination with binimetinib with or without talazoparib in patients with advanced or metastatic Ras-Mutant Solid Tumors

Not yet recruiting
1/2
127
Europe
Avelumab, Binimetinib, Talazoparib, MSB0010718C, PF-06944076 (MDV3800; BMN 673), Concentrate for solution for infusion, Film-coated tablet, Capsule, Bavencio
Pfizer Inc, 253 East 42nd Street, New York, NY 10017, Pfizer Inc
locally advanced or metastatic KRAS-or NRAS-mutant NSCLC, mPDAC (regardless of KRAS status), and other KRAS-or NRAS-mutant solid tumors, Solid Tumours, Diseases [C] - Cancer [C04]
 
 
BTCRC-BRE18-337, NCT03911973: Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

Active, not recruiting
1/2
37
US
Gedatolisib, Talazoparib
Kari Wisinski, Pfizer, Celcuity Inc
TNBC - Triple-Negative Breast Cancer
07/24
07/24
NCT04039230: Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

Recruiting
1/2
75
US
Talazoparib, Sacituzumab Govitecan
Massachusetts General Hospital, Pfizer
Breast Cancer
12/25
12/26
TALAVE, NCT03964532: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

Active, not recruiting
1/2
24
US
Talazoparib, Talzenna, Avelumab, Bavencio
Georgetown University, Pfizer
Breast Cancer
03/25
03/25
TRESR, NCT04497116 / 2020-000301-87: Study of RP-3500, Camonsertib, in Advanced Solid Tumors

Active, not recruiting
1/2
285
Europe, Canada, US
RP-3500 (camonsertib), Talazoparib, Gemcitabine Injection
Repare Therapeutics, Roche Pharma AG
Advanced Solid Tumor
07/25
12/25
NCT04337970: Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

Active, not recruiting
1/2
23
US
Talazoparib, Axitinib
Memorial Sloan Kettering Cancer Center
Kidney Cancer, Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
10/25
10/25
NCT05035745: Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Recruiting
1/2
63
RoW
Talazoparib, Selinexor
National University Hospital, Singapore
Advanced Refractory Solid Tumors, Advanced Triple Negative Breast Cancers, Metastatic Triple Negative Breast Cancers
11/24
11/25
AFT-50 EndoMAP, NCT04486352: A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Recruiting
1/2
148
US
Atezolizumab - 28 Day Cycle, Tecentriq, L01XC32, Bevacizumab, Avastin, L01XC07, Ipatasertib, RG7440, GDC-0068, Talazoparib, Talzenna, L01XX60, Trastuzumab emtansine, T-DM1, Kadcyla, Tiragolumab, Atezolizumab - 21 Day Cycle, Inavolisib, GDC-0077, Letrozole, Femara, Giredestrant, GDC-9545, Abemaciclib, Verzenio
Alliance Foundation Trials, LLC., Genentech, Inc., Foundation Medicine, Pfizer, Eli Lilly and Company
Endometrial Cancer
10/25
10/26
ONITT, NCT04901702 / 2021-003570-31: Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Active, not recruiting
1/2
46
Canada, US
Onivyde, Nanoliposomal irinotecan, Talazoparib, BMN 673, Talzenna, Temozolomide, Temodar, Temodal
St. Jude Children's Research Hospital, Pfizer, Ipsen
Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Wilms Tumor, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
12/25
12/25
NCT05898399: Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Recruiting
1/2
260
US
ART6043, Olaparib, Niraparib
Artios Pharma Ltd
Advanced Solid Tumor, Metastatic Solid Tumor
05/26
12/26
NAKIP-AML, NCT05319249: Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia

Not yet recruiting
1/2
54
NA
NK cells, Haploidentical human allogeneic NK cells, Talazoparib 1 MG [Talzenna], Talzenna
German Cancer Research Center
Acute Myeloid Leukemia
06/28
06/28
NCT04019327: A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer

Active, not recruiting
1/2
16
US
Talazoparib, Tala, Temozolomide, TMZ
Memorial Sloan Kettering Cancer Center
Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm, Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
07/27
07/27
NCI9782, NCT02317874: Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer

Completed
1
43
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Talazoparib, BMN 673, BMN-673
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
04/19
05/22
NCT03343054: A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Completed
1
28
Japan
talazoparib
Pfizer
Neoplasms, Breast Neoplasms
01/21
07/24
BrUOG 390, NCT04598321: Neoadjuvant Treatment With Talazoparib

Terminated
1
1
US
Talazoparib Oral Capsule, Talzenna
Brown University, Pfizer, Lifespan
BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer, Fallopian Tube Cancer, High Grade Serous Carcinoma
11/22
12/22
NCT04703920: Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Completed
1
26
US
Talazoparib, Belinostat
University of Michigan Rogel Cancer Center, Pfizer, Acrotech Biopharma Inc.
Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Ovarian Carcinoma, Metastic or Unresectable Pancreatic Adenocarcinoma
12/24
01/25
NCT03426254: Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

Checkmark Comparison of subcutaneous talazoparib versus oral talazoparib
Feb 2018 - Feb 2018: Comparison of subcutaneous talazoparib versus oral talazoparib
Withdrawn
1
10
RoW
Injections Subcutaneously Talazoparib, MDV3800, BMN673, Oral capsules Talazoparib
Center Trials & Treatment, BioGene Pharmaceutical
Advanced or Recurrent Solid Tumors, Breast Neoplasm
12/23
01/24
NCT04134884: Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Completed
1
34
US
Talazoparib, ASTX727
Kathy Miller, Pfizer, Astex Pharmaceuticals, Inc., Van Andel Institute Stand Up to Cancer Team
Metastatic Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Tumor
01/24
03/24
NCT06218628: Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Recruiting
1
24
US
Talazoparib, talzenna, pacritinib, vonjo
Fox Chase Cancer Center
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Chronic Myelomonocytic Leukemia, Polycythemia Vera, Essential Thrombocytosis
08/29
08/30
REPAIR, NCT05425862: Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

Suspended
1
48
RoW
Pidnarulex, CX-5461, Talazoparib
Peter MacCallum Cancer Centre, Australia
Metastatic Castration Resistant Prostate Cancer (mCRPC)
07/24
12/25
NCT04170946: Talazoparib and Thoracic RT for ES-SCLC

Recruiting
1
24
Canada
Talazoparib in Combination with Low Dose Radiotherapy (RT)
University Health Network, Toronto, Pfizer
Lung Cancer, Small-Cell Lung Cancer
09/27
09/27
NCT03968406: Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

Recruiting
1
24
US
Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Talazoparib, BMN 673, BMN-673
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Vaginal Carcinoma, Stage IV Cervical Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8
10/27
10/27
NCT04207190: Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

Completed
1
24
US
Gemtuzumab Ozogamicin, Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody, CDP-771, CMA-676, gemtuzumab, hP67.6-Calicheamicin, Mylotarg, WAY-CMA-676, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Talazoparib, BMN 673, BMN-673, Talazoparib Tosylate, Talzenna
Roswell Park Cancer Institute, Pfizer
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
05/24
06/24
NCT03974217: Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Recruiting
1
12
US
Talazoparib, Talzenna, Decitabine, Dacogen
Dana-Farber Cancer Institute, Pfizer
Leukemia
12/24
06/25
NCT04991480: A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Active, not recruiting
1
390
Europe, US
ART4215, Talazoparib, Talzenna, Niraparib, Zejula
Artios Pharma Ltd
Advanced Cancer, Metastatic Cancer, Breast Cancer
03/26
03/26
NCT04846478: Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

Active, not recruiting
1
35
US
Talazoparib, Talzenna, Tazemetostat, Tazverik, EPZ-6438
Dana-Farber Cancer Institute, Epizyme, Inc., Pfizer, National Cancer Institute (NCI)
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
03/26
09/26
NCT04693468: Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

Recruiting
1
111
US
Axitinib, AG-013736, AG013736, Inlyta, Crizotinib, MET Tyrosine Kinase Inhibitor PF-02341066, PF-02341066, PF-2341066, Xalkori, Palbociclib Isethionate, PD 0332991-0054, PF-00080665-73, Talazoparib Tosylate, Talzenna
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
12/27
12/27
PARLuNET, NCT05053854: PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours

Recruiting
1
24
RoW
Talazoparib, Combination product: 177Lu-DOTA-Octreotate
Peter MacCallum Cancer Centre, Australia
Neuroendocrine Tumors
06/29
06/29
NCT04511039: Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Recruiting
1
45
US
Trifluridine and Tipiracil Hydrochloride, 733030-01-8, Lonsurf, TAS 102,, Thymidine, Tipiracil Hydrochlorid Mixture with Trifluridine, Trifluridine/Tipiracil, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102, Talazoparib Tosylate, Talzenna
Roswell Park Cancer Institute, Pfizer
Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma A, Locally Advanced Colorectal Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
09/26
04/27
PARPAML, NCT05101551: Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Recruiting
1
34
US
Talazoparib, Talzenna, Topotecan, Hycamtin, Gemcitabine, Gemzar, Infugem
Norman J. Lacayo, Gateway for Cancer Research
Acute Myeloid Leukemia
03/26
03/26
ArteRIB, NCT04774406: Arterial Hypertension Related to PARP Inhibitors

Completed
N/A
2336
Europe
olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib
University Hospital, Caen
Cancer
05/21
09/22
TAILOR, NCT04801966: Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

Terminated
N/A
3
RoW
Trametinib, Cobimetinib, Binimetinib, Alpelisib, Vemurafenib, Dabrafenib, Encorafenib, Palbociclib, Olaparib, Ribociclib, Abemaciclib, Talazoparib, Nivolumab, Atezolizumab, Pembrolizumab
Peter MacCallum Cancer Centre, Australia
Cancer
12/22
12/22
NCT05650476: Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Available
N/A
NA
Talazoparib
Pfizer, In Expanded Access, treating physicians are the Sponsors
Metastatic Castration-Resistant Prostate Cancer
 
 
NCT06735742: A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer

Not yet recruiting
N/A
37
NA
Pfizer
Breast Cancer
07/31
07/31
NCT06733337: A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.

Not yet recruiting
N/A
104
NA
Pfizer
Prostate Cancer
06/29
06/29
NCT04982848: Korea Post Marketing Surveillance (PMS) Study of Talzenna®

Not yet recruiting
N/A
600
NA
Talzenna
Pfizer
Breast Neoplasms
11/26
11/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Talzenna (talazoparib) / Pfizer
TALAPRO-2, NCT03395197 / 2017-003295-31: Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

Hourglass May 2023 - Dec 2023 : Market entry in combination with Xtandi for metastatic CRPC (based on TALAPRO-2 trial)
Hourglass Oct 2022 - Dec 2022 : Approval for 1L mCRPC in combination with Xtandi
Checkmark Data from TALAPRO-2 trial in combination with Xtandi for metastatic CRPC
Oct 2022 - Oct 2022: Data from TALAPRO-2 trial in combination with Xtandi for metastatic CRPC
Checkmark Data from TALAPRO-2 trial in combination with Xtandi for mCRPC
More
Active, not recruiting
3
1054
Europe, Canada, Japan, US, RoW
Talazoparib with enzalutamide, Placebo with enzalutamide
Pfizer, Astellas Pharma Inc
mCRPC
10/22
12/25
TALAPRO-3, NCT04821622 / 2021-000248-23: Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Calendar Jan 2025 - Jun 2025: From TALAPRO-3 trial for 1L metastatic CRPC
Hourglass May 2023 - Dec 2023 : Market entry in combination with Xtandi for metastatic CRPC (based on TALAPRO-2 trial)
Active, not recruiting
3
599
Europe, Canada, Japan, US, RoW
talazoparib plus enzalutamide, Combination arm, Placebo plus enzalutamide, Monotherapy arm
Pfizer, Astellas Pharma Inc
Prostate Cancer
09/25
08/27
NCT05059522 / 2021-002457-29: Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Active, not recruiting
3
67
Europe, Canada, Japan, US, RoW
Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib, CMP 001, Utomilumab, PF04518600
Pfizer
Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors
09/26
09/26
2018-002914-10: FUnctional selection of advanced breast cancer patients for Talazoparib treatment Using the REpair Capacity (RECAP) test: The FUTURE trial Selectie van patiënten met uitgezaaide borstkanker voor behandeling met Talazoparib met behulp van de REpair Capacity (RECAP) test: De FUTURE studie

Not yet recruiting
2
66
Europe
Talazoparib, Capsule
Erasmus MC Cancer Institute, Pfizer
Advanced or metastatic breast cancer Vergevorderd of gemetastaseerd mammacarcinoom, Advanced or metastatic breast cancer Vergevorderde of uitgezaaide borstkanker, Diseases [C] - Cancer [C04]
 
 
FUTURE, NCT06193525: FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test

Recruiting
2
66
Europe
Talazoparib, Talazoparib 1 MG Oral Capsule [Talzenna]
Erasmus Medical Center, Leiden University Medical Center, University Medical Center Groningen
Advanced Breast Cancer
12/25
12/25
NCT02401347: Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Checkmark Genomic analysis from the Beyond BRCA clinical trial
Dec 2020 - Dec 2020: Genomic analysis from the Beyond BRCA clinical trial
Checkmark Initiation of P2 Beyond BRCA registrational trial in breast cancer
Aug 2015 - May 2015: Initiation of P2 Beyond BRCA registrational trial in breast cancer
Completed
2
21
US
Talazoparib Tosylate, BMN 673
Melinda Telli, BioMarin Pharmaceutical, Pfizer
Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer
12/19
12/22
2019-004388-37: A Three-Cohort Phase II trial to Assess the Efficacy of a Maintenance Treatment with TALAzoparib following First Line Platinum-based Chemotherapy in Pleural and Malignant Peritoneal MESOthelioma Patients: TALAMESO

Not yet recruiting
2
40
Europe
Capsule, TALZENNA
Hospices Civils de Lyon, PFIZER
This study involves adults subjects with advanced malignant pleural (cohort A) or peritoneal (cohorts B1 and B2) mesothelioma.The cohorts B1 will be patient populations with non-resected or incompletely resected disease and cohort B2, with completely resected disease., This study involves adults subjects with advanced malignant pleural (cohort A) or peritoneal (cohorts B1 and B2) mesothelioma., Not possible to specify
 
 
Talapro-1, NCT03148795 / 2016-002036-32: A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

Checkmark Additional data for metastatic castration-resistant 2L prostate cancer from TALAPRO-1 study
Aug 2021 - Aug 2021: Additional data for metastatic castration-resistant 2L prostate cancer from TALAPRO-1 study
Checkmark From TALAPRO-1 study for heavily pretreated mCRPC
Apr 2021 - Apr 2021: From TALAPRO-1 study for heavily pretreated mCRPC
Checkmark From TALAPRO-1 trial for mCRPC at ASCO 2020
More
Completed
2
128
Europe, US, RoW
Talazoparib, MDV3800
Pfizer, Medivation, Inc.
Prostate Cancer
09/20
03/23
2020-001105-24: TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma: A single-arm Phase 2 trial TALazoparib et Avelumab en tant que traitement d'entretien dans le carcinome urothélial métastatique ou localement avancé: un essai de phase 2 à un seul bras

Not yet recruiting
2
50
Europe
Avelumab, Talazoparib, MSB0010718C, PF-06944076, Concentrate for solution for infusion, Capsule, BAVENCIO, TALZENNA
Centre François Baclesse, Centre François Baclesse
Maintenance treatment in patients with locally advanced/metastatic urothelial carcinoma. Traitement de maintenance des patients présentant un carcinome urothelial métastatique ou localement avancé, Maintenance treatment in patients with locally advanced/metastatic urothelial carcinoma. Traitement de maintenance des patients présentant un carcinome urothelial métastatique ou localement avancé, Diseases [C] - Cancer [C04]
 
 
2020-003395-41: Ex vivo drug sensitivity in metastatic colorectal cancer

Not yet recruiting
2
45
Europe
Alectinib, Crizotinib, Dasatinib, Everolimus, Gemcitabine, Idelalisib, Larotrectinib, Methotrexate, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Trastuzumab, Talazoparib, Venetoclax, Cetuximab, Encorafinib, Capsule, hard, Film-coated tablet, Tablet, Infusion, Injection, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Alecensa, Xalkori, Sprycel, Afinitor, Gemcitabine Accord, Zydelig, Vitrakvi, Methotrexat Accord, Ibrance, Farydak, Keytruda, Perjeta, Herceptin, Talzenna, Venclyxto, Erbitux, Braftovi
Oslo University Hospital, Oslo University Hospital
Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Diseases [C] - Cancer [C04]
 
 
TALAMESO, NCT04462809 / 2019-004388-37: Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma

Not yet recruiting
2
40
NA
Talazoparib
Hospices Civils de Lyon, PFIZER
Advanced Malignant Pleural or Peritoneal Mesothelioma
03/21
10/24
Young-PALETTA, NCT04819243: PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study

Recruiting
2
178
RoW
Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib, Atezolizumab, Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib,
Samsung Medical Center
Premenopausal HR+/HER2- Metastatic Breast Cancer
12/25
12/27
LUNG-MAP Sub-Study, NCT04173507: Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

Completed
2
47
US
Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Talazoparib, BMN 673, BMN-673, Talazoparib Tosylate, Talzenna
SWOG Cancer Research Network, National Cancer Institute (NCI)
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
11/21
05/24
NCT04824937: Telaglenastat + Talazoparib In Prostate Cancer

Not yet recruiting
2
30
US
Telaglenastat, CB 839, Talazoparib, Taken orally
Massachusetts General Hospital, Calithera Biosciences, Inc, Pfizer, Prostate Cancer Foundation
Prostate Cancer Metastatic
12/21
12/21
NCT03565991 / 2018-000345-39: Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Checkmark Results from JAVELIN BRCA/ATM trial for advanced BRCA1/2-altered or ATM-altered solid tumors
Nov 2022 - Nov 2022: Results from JAVELIN BRCA/ATM trial for advanced BRCA1/2-altered or ATM-altered solid tumors
Checkmark For JAVELIN BRCA/ATM trial in combination with talazoparib for BRCA or ATM mutant solid tumors
Mar 2022 - Mar 2022: For JAVELIN BRCA/ATM trial in combination with talazoparib for BRCA or ATM mutant solid tumors
Terminated
2
202
Europe, Japan, US
Avelumab, Bavencio, Talazoparib, MDV3800, BMN 673
Pfizer
Locally Advanced or Metastatic Solid Tumors, Genes, BRCA 1
03/22
02/23
HCRN BRE19-433, NCT04690855: A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer

Terminated
2
1
US
Talazoparib, Talzenna, Atezolizumab, Tecentriq, Radiation
Mylin A. Torres, MD, Genentech, Inc., Pfizer, Emory University
Breast Cancer, Triple Negative Breast Cancer
02/22
12/22
TAC-GReD, NCT04740190: Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

Recruiting
2
33
RoW
Talazoparib, Carboplatin, whole brain irradiation
The University of Hong Kong
Recurrent Glioma, Recurrent Glioblastoma, Poly ADP Ribose Polymerase (PARP) Inhibitor, PTEN Gene Inactivation, IDH Mutation
12/22
12/23
NCT04892693: Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Recruiting
2
70
RoW
Talazoparib Oral Capsule, Single arm; Talazoparib
Seoul National University Hospital
Advanced Breast Cancer
05/27
05/27
TALASUR, NCT04678362 / 2020-001105-24: TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma

Recruiting
2
50
Europe
Talazoparib + Avelumab
Centre Francois Baclesse, Pfizer
Urothelial Carcinoma
07/23
12/25
TRIO-US L-07, NCT03672773: Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Recruiting
2
28
US
Talazoparib, BMN 673, BMN-673, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
Jonsson Comprehensive Cancer Center, Translational Research in Oncology, Pfizer
Recurrent Extensive Stage Small Cell Lung Carcinoma, Refractory Extensive Stage Small Cell Lung Carcinoma
10/25
10/26
NCT04187833: Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes

Completed
2
8
US
Nivolumab, Opdivo, Talazoparib, Talzenna
Case Comprehensive Cancer Center
Metastatic or Unresectable Melanoma
10/23
10/23
NCT04550494: Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Recruiting
2
36
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Talazoparib, BMN 673, BMN-673, BMN673
National Cancer Institute (NCI)
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, HER2-Positive Breast Carcinoma, Locally Advanced Breast Carcinoma, Locally Advanced Gastric Carcinoma, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Ovarian Carcinoma, Locally Advanced Pancreatic Carcinoma, Locally Advanced Prostate Carcinoma, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Prostate Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Breast Carcinoma, Recurrent Gastric Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
12/26
12/26
NCT04734730: Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Recruiting
2
70
US
Abiraterone Acetate, CB7630, Yonsa, Zytiga, Bicalutamide, Casodex, Cosudex, ICI 176,334, ICI 176334, Degarelix, FE200486, Firmagon, Goserelin Acetate, ZDX, Zoladex, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Questionnaire Administration, Talazoparib, BMN 673, BMN-673
City of Hope Medical Center, National Cancer Institute (NCI)
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
08/27
08/27
NCT04692662: Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response

Recruiting
2
36
US
talazoparib
National Cancer Institute (NCI)
Solid Tumors
12/23
12/23
NCT03990896: Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Recruiting
2
30
US
Talazoparib, Talzenna
Massachusetts General Hospital, Pfizer
Breast Cancer
07/25
12/25
NCT03901469 / 2018-003906-26: A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer

Terminated
2
115
Europe, US, RoW
ZEN003694, ZEN-3694, Talazoparib, Talzenna
Zenith Epigenetics, Pfizer, Newsoara Biopharma Co., Ltd.
Triple Negative Breast Cancer
03/24
03/24
KCSG BR21-10, NCT04755868: Talazoparib Maintenance Therapy in Triple-negative Breast Cancer

Not yet recruiting
2
206
RoW
Talazoparib, Placebo
Yonsei University
TNBC - Triple-Negative Breast Cancer
03/24
03/24
NCT04756765: Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer

Recruiting
2
30
US
Talazoparib Tosylate, Talzenna, BMN-673
Stanford University, Pfizer
Breast Cancer, Advanced Breast Cancer
03/25
03/25
NCT05288127: Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature

Recruiting
2
55
RoW
Talazoparib
University of Malaya, Cancer Research Malaysia, Pfizer, Pantai Hospital Kuala Lumpur, Hospital Sultan Ismail
HRD 100 Gene Expression High, Triple Negative Breast Cancer
06/24
11/25
TEAM PC, NCT06582628: Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer:

Recruiting
2
78
Europe
Enzalutamide capsule, Enzalutamide capsule and Talazoparib capsule
Fundacion Oncosur
Metastatic Prostate Cancer
01/26
10/27
NCT04068831: Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

Completed
2
18
US
Talazoparib, BMN-673, Avelumab
Memorial Sloan Kettering Cancer Center
Metastatic Renal Cell Carcinoma, Fumarate Hydratase Deficient Renal Cell Carcinoma, Succinate Dehydrogenase Deficient Renal Cell Carcinoma
12/23
12/23
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25
TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Recruiting
2
4200
US
Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi
American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
12/27
12/28
ChiCTR2300078496: A single-center, non-interventional study to evaluate effectiveness and safety of Talazoparib in combination with Enzalutamide in first-line treatment of patients with HRR gene-mutated metastatic castration-resistant prostate cancer(mCRPC) in China

Recruiting
2
10
 
none
Shanghai Jiaotong University School of Medicine Ruijin-Hainan Hospital(Hainan Boao Research Hopspital); Shanghai Jiaotong University School of Medicine Ruijin-Hainan Hospital(Hainan Boao Research Hopspital), Pfizer,only funding
Prostate cancer
 
 
NCT02912572: Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

Active, not recruiting
2
106
US
Avelumab, Talazoparib, Axitinib
Dana-Farber Cancer Institute, Pfizer
Metastatic Endometrial Cancer
11/23
11/26
TALENT, NCT06844383: A Study of Talazoparib with or Without Enzalutamide in People with Prostate Cancer Who Have Previously Received Abiraterone Acetate

Not yet recruiting
2
126
US
Talazoparib with enzalutamide, Talzenna, Xtandi, Talazoparib
Prostate Cancer Clinical Trials Consortium, Pfizer, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center
Prostate Cancer (Adenocarcinoma), MCRPC (metastatic Castration-resistant Prostate Cancer)
12/28
03/29
ZZFIRST, NCT04332744 / 2019-003096-20: Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)

Active, not recruiting
2
54
Europe
Enzalutamide, Xtandi, Talazoparib, (PF-06944076)
MedSIR, Pfizer
Metastatic Prostate Cancer
05/25
07/25
NCT06762808: Phase II Study of Atezolizumab and Tiragolumab With ctDNA for HPV-positive SCC

Not yet recruiting
2
55
US
Atezolizumab, Talazoparib
M.D. Anderson Cancer Center, Genentech, Inc., Strategic Alliance
Squamous Cell Carcinoma
12/26
12/28
NCT05327010: Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Recruiting
2
88
US
BET Bromodomain Inhibitor ZEN-3694, BETi ZEN-3694, ZEN 3694, ZEN-3694, ZEN003694, Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Diagnostic Imaging Testing, Diagnostic Imaging, Medical Imaging, Talazoparib, BMN 673, BMN-673, BMN673
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
08/25
08/25
NCT05071937: ZEN003694 Combined with Talazoparib in Patients with Recurrent Ovarian Cancer

Recruiting
2
33
US
ZEN003694, Talazoparib
Alexander B Olawaiye, MD, Pfizer, Zenith Epigenetics
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
12/29
03/31
SWOG S1929, NCT04334941: Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker

Active, not recruiting
2
94
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Talazoparib, BMN 673, BMN-673, BMN673
National Cancer Institute (NCI)
Extensive Stage Lung Small Cell Carcinoma
11/25
11/25
NCT02286687: Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

Active, not recruiting
2
150
US
Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib, BMN 673, BMN-673
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Neoplasm, ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Metastatic Malignant Neoplasm, PALB2 Gene Mutation, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
12/25
12/25
NCT05142241: Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

Suspended
2
34
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Talazoparib, BMN 673, BMN-673, BMN673, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
National Cancer Institute (NCI)
Adrenal Gland Pheochromocytoma, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Paraganglioma
04/26
04/26
Strata PATH, NCT05097599: StrataPATH™ (Precision Indications for Approved Therapies)

Terminated
2
11
US
lorlatinib, encorafenib + binimetinib, talazoparib, sacituzumab govitecan, axitinib, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, enfortumab vedotin, Padcev
Strata Oncology, Merck Sharp & Dohme LLC, Pfizer, Gilead Sciences
Cancer, Advanced Solid Tumor
06/24
06/24
NCT05873192: Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

Not yet recruiting
2
30
US
ADT, Hormone Therapy, Enzalutamide, MDV3100, XTANDI®, Talazoparib, BMN 673, Talazoparib tosylate, Degarelix, Luprolide
M.D. Anderson Cancer Center
Prostate Cancer
12/26
12/28
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

Active, not recruiting
2
197
US
Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077
Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer Research
Breast Cancer, Triple Negative Breast Cancer
01/29
01/34
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
EVIDENT, NCT05725200 / 2020-003395-41: Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Recruiting
2
40
Europe
Alectinib, Cetuximab, Crizotinib, Dasatinib, Everolimus, Encorafenib, Gemcitabine, Idelalisib, Larotrectinib, Methotrexate, Palbociclib, Panobinostat, Pembrolizumab, Petrozumab, Trastuzumab, Talazoparib, Venetoclax
Oslo University Hospital, Oslo University Hospital
Metastatic Colorectal Cancer
12/38
12/40
NCT02878785: Decitabine and Talazoparib in Untreated AML and R/R AML

Completed
1/2
25
US
Decitabine, dacogen, talazoparib, BMN673; MDV3800
University of Maryland, Baltimore, Pfizer, Van Andel Research Institute
Acute Myeloid Leukemia
01/20
11/20
2018-000124-34: Safety and clinical Activity of avelumab in combination with binimetinib with or without talazoparib in patients with advanced or metastatic Ras-Mutant Solid Tumors

Not yet recruiting
1/2
127
Europe
Avelumab, Binimetinib, Talazoparib, MSB0010718C, PF-06944076 (MDV3800; BMN 673), Concentrate for solution for infusion, Film-coated tablet, Capsule, Bavencio
Pfizer Inc, 253 East 42nd Street, New York, NY 10017, Pfizer Inc
locally advanced or metastatic KRAS-or NRAS-mutant NSCLC, mPDAC (regardless of KRAS status), and other KRAS-or NRAS-mutant solid tumors, Solid Tumours, Diseases [C] - Cancer [C04]
 
 
BTCRC-BRE18-337, NCT03911973: Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

Active, not recruiting
1/2
37
US
Gedatolisib, Talazoparib
Kari Wisinski, Pfizer, Celcuity Inc
TNBC - Triple-Negative Breast Cancer
07/24
07/24
NCT04039230: Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.

Recruiting
1/2
75
US
Talazoparib, Sacituzumab Govitecan
Massachusetts General Hospital, Pfizer
Breast Cancer
12/25
12/26
TALAVE, NCT03964532: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

Active, not recruiting
1/2
24
US
Talazoparib, Talzenna, Avelumab, Bavencio
Georgetown University, Pfizer
Breast Cancer
03/25
03/25
TRESR, NCT04497116 / 2020-000301-87: Study of RP-3500, Camonsertib, in Advanced Solid Tumors

Active, not recruiting
1/2
285
Europe, Canada, US
RP-3500 (camonsertib), Talazoparib, Gemcitabine Injection
Repare Therapeutics, Roche Pharma AG
Advanced Solid Tumor
07/25
12/25
NCT04337970: Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

Active, not recruiting
1/2
23
US
Talazoparib, Axitinib
Memorial Sloan Kettering Cancer Center
Kidney Cancer, Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
10/25
10/25
NCT05035745: Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

Recruiting
1/2
63
RoW
Talazoparib, Selinexor
National University Hospital, Singapore
Advanced Refractory Solid Tumors, Advanced Triple Negative Breast Cancers, Metastatic Triple Negative Breast Cancers
11/24
11/25
AFT-50 EndoMAP, NCT04486352: A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Recruiting
1/2
148
US
Atezolizumab - 28 Day Cycle, Tecentriq, L01XC32, Bevacizumab, Avastin, L01XC07, Ipatasertib, RG7440, GDC-0068, Talazoparib, Talzenna, L01XX60, Trastuzumab emtansine, T-DM1, Kadcyla, Tiragolumab, Atezolizumab - 21 Day Cycle, Inavolisib, GDC-0077, Letrozole, Femara, Giredestrant, GDC-9545, Abemaciclib, Verzenio
Alliance Foundation Trials, LLC., Genentech, Inc., Foundation Medicine, Pfizer, Eli Lilly and Company
Endometrial Cancer
10/25
10/26
ONITT, NCT04901702 / 2021-003570-31: Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Active, not recruiting
1/2
46
Canada, US
Onivyde, Nanoliposomal irinotecan, Talazoparib, BMN 673, Talzenna, Temozolomide, Temodar, Temodal
St. Jude Children's Research Hospital, Pfizer, Ipsen
Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Wilms Tumor, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
12/25
12/25
NCT05898399: Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Recruiting
1/2
260
US
ART6043, Olaparib, Niraparib
Artios Pharma Ltd
Advanced Solid Tumor, Metastatic Solid Tumor
05/26
12/26
NAKIP-AML, NCT05319249: Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia

Not yet recruiting
1/2
54
NA
NK cells, Haploidentical human allogeneic NK cells, Talazoparib 1 MG [Talzenna], Talzenna
German Cancer Research Center
Acute Myeloid Leukemia
06/28
06/28
NCT04019327: A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer

Active, not recruiting
1/2
16
US
Talazoparib, Tala, Temozolomide, TMZ
Memorial Sloan Kettering Cancer Center
Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm, Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
07/27
07/27
NCI9782, NCT02317874: Testing the Addition of the Anti-Cancer Drug Talazoparib to the Combination of Carboplatin and Paclitaxel for the Treatment of Advanced Cancer

Completed
1
43
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Talazoparib, BMN 673, BMN-673
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
04/19
05/22
NCT03343054: A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors

Completed
1
28
Japan
talazoparib
Pfizer
Neoplasms, Breast Neoplasms
01/21
07/24
BrUOG 390, NCT04598321: Neoadjuvant Treatment With Talazoparib

Terminated
1
1
US
Talazoparib Oral Capsule, Talzenna
Brown University, Pfizer, Lifespan
BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer, Fallopian Tube Cancer, High Grade Serous Carcinoma
11/22
12/22
NCT04703920: Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Completed
1
26
US
Talazoparib, Belinostat
University of Michigan Rogel Cancer Center, Pfizer, Acrotech Biopharma Inc.
Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Ovarian Carcinoma, Metastic or Unresectable Pancreatic Adenocarcinoma
12/24
01/25
NCT03426254: Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

Checkmark Comparison of subcutaneous talazoparib versus oral talazoparib
Feb 2018 - Feb 2018: Comparison of subcutaneous talazoparib versus oral talazoparib
Withdrawn
1
10
RoW
Injections Subcutaneously Talazoparib, MDV3800, BMN673, Oral capsules Talazoparib
Center Trials & Treatment, BioGene Pharmaceutical
Advanced or Recurrent Solid Tumors, Breast Neoplasm
12/23
01/24
NCT04134884: Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Completed
1
34
US
Talazoparib, ASTX727
Kathy Miller, Pfizer, Astex Pharmaceuticals, Inc., Van Andel Institute Stand Up to Cancer Team
Metastatic Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Tumor
01/24
03/24
NCT06218628: Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Recruiting
1
24
US
Talazoparib, talzenna, pacritinib, vonjo
Fox Chase Cancer Center
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Chronic Myelomonocytic Leukemia, Polycythemia Vera, Essential Thrombocytosis
08/29
08/30
REPAIR, NCT05425862: Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

Suspended
1
48
RoW
Pidnarulex, CX-5461, Talazoparib
Peter MacCallum Cancer Centre, Australia
Metastatic Castration Resistant Prostate Cancer (mCRPC)
07/24
12/25
NCT04170946: Talazoparib and Thoracic RT for ES-SCLC

Recruiting
1
24
Canada
Talazoparib in Combination with Low Dose Radiotherapy (RT)
University Health Network, Toronto, Pfizer
Lung Cancer, Small-Cell Lung Cancer
09/27
09/27
NCT03968406: Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers

Recruiting
1
24
US
Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Talazoparib, BMN 673, BMN-673
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Vaginal Carcinoma, Stage IV Cervical Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IV Vaginal Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Stage IVB Vaginal Cancer AJCC v8
10/27
10/27
NCT04207190: Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

Completed
1
24
US
Gemtuzumab Ozogamicin, Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody, CDP-771, CMA-676, gemtuzumab, hP67.6-Calicheamicin, Mylotarg, WAY-CMA-676, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Talazoparib, BMN 673, BMN-673, Talazoparib Tosylate, Talzenna
Roswell Park Cancer Institute, Pfizer
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
05/24
06/24
NCT03974217: Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Recruiting
1
12
US
Talazoparib, Talzenna, Decitabine, Dacogen
Dana-Farber Cancer Institute, Pfizer
Leukemia
12/24
06/25
NCT04991480: A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Active, not recruiting
1
390
Europe, US
ART4215, Talazoparib, Talzenna, Niraparib, Zejula
Artios Pharma Ltd
Advanced Cancer, Metastatic Cancer, Breast Cancer
03/26
03/26
NCT04846478: Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

Active, not recruiting
1
35
US
Talazoparib, Talzenna, Tazemetostat, Tazverik, EPZ-6438
Dana-Farber Cancer Institute, Epizyme, Inc., Pfizer, National Cancer Institute (NCI)
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
03/26
09/26
NCT04693468: Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

Recruiting
1
111
US
Axitinib, AG-013736, AG013736, Inlyta, Crizotinib, MET Tyrosine Kinase Inhibitor PF-02341066, PF-02341066, PF-2341066, Xalkori, Palbociclib Isethionate, PD 0332991-0054, PF-00080665-73, Talazoparib Tosylate, Talzenna
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
12/27
12/27
PARLuNET, NCT05053854: PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours

Recruiting
1
24
RoW
Talazoparib, Combination product: 177Lu-DOTA-Octreotate
Peter MacCallum Cancer Centre, Australia
Neuroendocrine Tumors
06/29
06/29
NCT04511039: Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Recruiting
1
45
US
Trifluridine and Tipiracil Hydrochloride, 733030-01-8, Lonsurf, TAS 102,, Thymidine, Tipiracil Hydrochlorid Mixture with Trifluridine, Trifluridine/Tipiracil, Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102, Talazoparib Tosylate, Talzenna
Roswell Park Cancer Institute, Pfizer
Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma A, Locally Advanced Colorectal Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
09/26
04/27
PARPAML, NCT05101551: Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

Recruiting
1
34
US
Talazoparib, Talzenna, Topotecan, Hycamtin, Gemcitabine, Gemzar, Infugem
Norman J. Lacayo, Gateway for Cancer Research
Acute Myeloid Leukemia
03/26
03/26
ArteRIB, NCT04774406: Arterial Hypertension Related to PARP Inhibitors

Completed
N/A
2336
Europe
olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib, fluzoparib
University Hospital, Caen
Cancer
05/21
09/22
TAILOR, NCT04801966: Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

Terminated
N/A
3
RoW
Trametinib, Cobimetinib, Binimetinib, Alpelisib, Vemurafenib, Dabrafenib, Encorafenib, Palbociclib, Olaparib, Ribociclib, Abemaciclib, Talazoparib, Nivolumab, Atezolizumab, Pembrolizumab
Peter MacCallum Cancer Centre, Australia
Cancer
12/22
12/22
NCT05650476: Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Available
N/A
NA
Talazoparib
Pfizer, In Expanded Access, treating physicians are the Sponsors
Metastatic Castration-Resistant Prostate Cancer
 
 
NCT06735742: A Study to Learn About the Safety of TALZENNA for the Treatment of Breast Cancer

Not yet recruiting
N/A
37
NA
Pfizer
Breast Cancer
07/31
07/31
NCT06733337: A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.

Not yet recruiting
N/A
104
NA
Pfizer
Prostate Cancer
06/29
06/29
NCT04982848: Korea Post Marketing Surveillance (PMS) Study of Talzenna®

Not yet recruiting
N/A
600
NA
Talzenna
Pfizer
Breast Neoplasms
11/26
11/26

Download Options